Reference Cases

ranking-stars-ribbon

1e

How Curium & NRG managed to be the first in Europe to stop using high enriched uranium for the production of molybdenum-99.

New

Successful partnerships led to new innovative processes.

2

How McMaster & NRG joined forces to guarantee a worldwide reliable delivery of iodine-125.

A few of our success stories

26 May 2020

In 2017, there was suddenly a worldwide shortage of iodine-125, used for brachytherapy for prostate cancer, because one of the large producers was temporarily shut down. McMaster & NRG joined forces for global supply.

21 July 2020

A complex project has been brought to a successful conclusion: the development and installation of a production process for xenon-133 gas.

22 July 2020

CISSPECT DESK-LAB represents a great leap forward for the development of radiopharmaceuticals and personalised drug discovery. Recently, we have developed the world’s first fully automated synthesis module, CISSPECT DESK-LAB, for the synthesis of Pt-195m cisplatin and other platinum compounds

29 July 2020

Producing medical isotopes using only low enriched uranium? After a challenging design process, Curium and NRG are the first in Europe to produce molybdenum-99 with low enriched uranium. Recognizing the commitments made during the Nuclear Summit 2014, to phase out high enriched uranium (HEU) based medical isotopes.